BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
BioLineRx Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.98−0.03 (-1.49%)
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.75 (−46.92%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BioLineRx Ltd. saw revenue fall 95.9% to $1.18M over fiscal 2025. Free cash flow was -$8.10M.
Revenue
$1.18M
-95.9% vs. a year earlier
Operating income
-$10.29M
FY2025
Free cash flow
-$8.10M
FY2025
EPS, diluted
$0.00
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $5.28B
- P/E ratio
- –
- Price to sales
- 4471.46
- Price to book
- 383.17
- Dividend yield
- –
- Free cash flow yield
- -0.15%
Fundamentals
- Revenue
- $1.18M
- EPS, diluted
- $0.00
- Free cash flow
- -$8.10M
- Book value per share
- $0.01
- Diluted shares
- 2.66B
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
$1.18M-95.9% YoY
Gross profit
$950.00K-95.2% YoY
Operating income
-$10.29M
EPS, diluted
$0.00
Free cash flow
-$8.10M
Reported period